Equities research analysts expect Albireo Pharma, Inc. (NASDAQ:ALBO) to post earnings per share (EPS) of ($1.72) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Albireo Pharma’s earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.53). Albireo Pharma reported earnings per share of ($2.23) in the same quarter last year, which suggests a positive year over year growth rate of 22.9%. The firm is expected to announce its next earnings results on Thursday, May 6th.
On average, analysts expect that Albireo Pharma will report full-year earnings of ($7.03) per share for the current financial year, with EPS estimates ranging from ($8.49) to ($5.96). For the next year, analysts expect that the firm will post earnings of ($4.49) per share, with EPS estimates ranging from ($5.97) to ($0.35). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Wednesday, February 24th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.90) by $0.60. Albireo Pharma had a negative net margin of 751.53% and a negative return on equity of 71.22%. The firm had revenue of $2.72 million for the quarter, compared to analyst estimates of $2.23 million.
ALBO has been the subject of a number of research analyst reports. Jefferies Financial Group lifted their price target on Albireo Pharma from $79.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, March 26th. Robert W. Baird reissued a “buy” rating and set a $67.00 target price on shares of Albireo Pharma in a report on Monday, March 1st. Piper Sandler increased their price target on Albireo Pharma from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Monday, March 8th. Finally, Zacks Investment Research upgraded shares of Albireo Pharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 17th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Albireo Pharma currently has a consensus rating of “Buy” and an average price target of $66.50.
Shares of ALBO stock traded up $0.35 on Friday, reaching $32.14. The stock had a trading volume of 259,536 shares, compared to its average volume of 170,035. Albireo Pharma has a 12 month low of $18.56 and a 12 month high of $49.00. The firm has a market capitalization of $614.32 million, a price-to-earnings ratio of -5.18 and a beta of 1.62. The firm’s 50-day moving average is $34.62 and its two-hundred day moving average is $36.34. The company has a quick ratio of 13.51, a current ratio of 13.52 and a debt-to-equity ratio of 0.04.
In related news, insider Jan Mattsson sold 31,470 shares of the firm’s stock in a transaction dated Wednesday, March 3rd. The shares were sold at an average price of $36.85, for a total transaction of $1,159,669.50. Insiders sold 32,394 shares of company stock worth $1,191,637 over the last 90 days. 5.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Albireo Pharma by 10.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,958 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 461 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of Albireo Pharma during the 3rd quarter worth $413,000. Cubist Systematic Strategies LLC increased its position in shares of Albireo Pharma by 27,319.2% in the third quarter. Cubist Systematic Strategies LLC now owns 7,129 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 7,103 shares during the period. California State Teachers Retirement System raised its stake in Albireo Pharma by 3.3% in the third quarter. California State Teachers Retirement System now owns 20,033 shares of the biopharmaceutical company’s stock valued at $669,000 after purchasing an additional 640 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Albireo Pharma during the third quarter worth about $227,000. Institutional investors and hedge funds own 85.65% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Read More: How a Put Option Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com